Background: Systemic fungal infections due to pathogenic yeasts are increasing in high-risk patients, and a need is emerging for novel antifungal agents with potent inhibitory activity toward a wide range of
No takes yet. Share an insight, caveat, or question.
Badiee et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: